Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma
DJ Thomson, KF Ho, L Ashcroft, K Denton, G Betts… - Acta …, 2015 - Taylor & Francis
Background. For stage II and III head and neck squamous cell carcinoma (HNSCC) treated
with radiotherapy alone, loco-regional recurrence is the main cause of treatment failure …
with radiotherapy alone, loco-regional recurrence is the main cause of treatment failure …
Concurrent cetuximab, cisplatin, and radiotherapy (RT) for loco-regionally advanced squamous cell carcinoma of the head and neck (SCCHN): updated results of a …
YB Su, DH Kraus, MJ Zelefsky, E Lis… - Journal of Clinical …, 2005 - ascopubs.org
5529 Background: We previously reported results of a phase 2 study of concurrent
cetuximab, a chimeric monoclonal antibody directed against the epidermal growth factor …
cetuximab, a chimeric monoclonal antibody directed against the epidermal growth factor …
A phase 2 open label, single-arm trial to evaluate the combination of cetuximab plus taxotere, cisplatin, and 5-flurouracil as an induction regimen in patients with …
R Mesía, S Vázquez, JJ Grau, JA García-Sáenz… - International Journal of …, 2016 - Elsevier
Purpose Despite treatment, prognosis of unresectable squamous cell carcinoma of the head
and neck (SCCHC) is dismal. Cetuximab therapy has proven to increase the clinical activity …
and neck (SCCHC) is dismal. Cetuximab therapy has proven to increase the clinical activity …
[PDF][PDF] Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck
This paper presents a summary of the evidence review group (ERG) report into the clinical
and cost-effectiveness of cetuximab plus radiotherapy for the treatment of locally advanced …
and cost-effectiveness of cetuximab plus radiotherapy for the treatment of locally advanced …
Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally …
M Suntharalingam, Y Kwok, O Goloubeva… - International Journal of …, 2012 - Elsevier
PURPOSE: To report the mature data of a prospective Phase II trial designed to evaluate the
efficacy of an epidermal growth factor receptor inhibitor cetuximab (CTX) added to the …
efficacy of an epidermal growth factor receptor inhibitor cetuximab (CTX) added to the …
Cetuximab/radiotherapy (CET+ RT) versus concomitant chemoradiotherapy (cCHT+ RT) with or without induction docetaxel/cisplatin/5-fluorouracil (TPF) in locally …
MG Ghi, A Paccagnella, D Ferrari, P Foa, F Nole… - 2012 - ascopubs.org
5513 Background: The standard treatment options for LASCCHN are cCHT+ RT or CET+
RT. Strategies to improve the efficacy with the integration of induction chemotherapy are …
RT. Strategies to improve the efficacy with the integration of induction chemotherapy are …
[引用][C] Cisplatin versus cetuximab combined with radiation therapy for definitive management of locally advanced squamous cell carcinoma of the head and neck: a …
Results Median follow-up was 2.6 years with a range of 1 to 6 years. Locoregional
recurrence rates were 8.2% in the cetuximab group and 6.3% in the cisplatin group. Distant …
recurrence rates were 8.2% in the cetuximab group and 6.3% in the cisplatin group. Distant …
Cetuximab: a review of its use in squamous cell carcinoma of the head and neck
JE Frampton - Drugs, 2010 - Springer
Cetuximab (Erbitux®) is a chimeric monoclonal antibody directed against the human
epidermal growth factor receptor (EGFR). EGFR is overexpressed and/or upregulated in …
epidermal growth factor receptor (EGFR). EGFR is overexpressed and/or upregulated in …
Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern …
AM Egloff, JW Lee, CJ Langer, H Quon, A Vaezi… - Clinical Cancer …, 2014 - AACR
Purpose: Treatment with cisplatin or cetuximab combined with radiotherapy each yield
superior survival in locally advanced squamous cell head and neck cancer (LA-SCCHN) …
superior survival in locally advanced squamous cell head and neck cancer (LA-SCCHN) …
Toxicity of cetuximab and radiotherapy in locally advanced head and neck cancer: a community-based experience
C Gillham, L Walsh, M Dunne, A McElroy… - Journal of Clinical …, 2008 - ascopubs.org
6020 Background: The combination of radiotherapy (RT) and cetuximab (CTX) represents a
new treatment option for patients with locally advanced head and neck cancer …
new treatment option for patients with locally advanced head and neck cancer …